BradleyCLeibovichMDFACS

Minimally Invasive Surgery, Surgical Oncology

David C. Utz, M.D. Professor of Urology, Department of Urology, Mayo Clinic Medical Director, Mayo Clinic Center for Digital Health

Join to view full profile

Dr. Leibovich is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Leibovich's full profile

Already have an account?

Office
200 1st St SW
Rochester, MN 55905
Phone+1 507-284-2511

Fax+1 507-284-4951

Education & Training

UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Minimally Invasive Urologic Surgery, 2001 - 2002
Indiana University School of MedicineFellowship, Minimally Invasive Urologic Surgery, 2001 - 2001
Mayo Clinic College of Medicine and Science (Rochester)Residency, Urology, 1995 - 2001
Albany Medical CollegeClass of 1995
Cornell UniversityBA, Biochemistry, 1984 - 1989

Certifications & Licensure

CA State Medical License 2001 - Present
IA State Medical License 2021 - 2025
MN State Medical License 1996 - 2025
SD State Medical License Active through 2025
AZ State Medical License 1997 - 1998
American Board of Urology Urology

Awards, Honors, & Recognition

Fellow (FACS) American College of Surgeons
Distinguished Mayo Clinician Award Mayo Clinic, 2015
Andrew C. Novick Award Kidney Cancer Association, 2014
Regional Top Doctor Castle Connolly, 2014
Teacher of the Year Hall of Fame Mayo Fellows Association, Mayo Clinic, 2007
Teacher of the Year Mayo Fellows Association, Mayo Clinic, 2004-2006
Excellence in Teaching Recognition Mayo Medical School, 2003-2004
Pfizer Scholars in Urology Award 2001
Best Clinical Presentation Award American Urological Association, 2000
James H. DeWeerd Travel Award 2000
Kelalis Resident Essy Award 1999
C. R. Bard Urological Award 1995
Daggett Trust Prize Daggett Trust, 1995
Alpha Omega Alpha Honor Medical Society 1993
Dean's commendation for scholastic excellence Albany Medical College, 1992
Join now to see all

Clinical Trials

Neoadjuvant Exisulind in Treating Patients Who Are Undergoing Radical Prostatectomy for Stage II or Stage III Prostate Cancer Start of enrollment: 2003 Aug 01
Completed
Phase 2
Exisulind Versus Placebo After Surgical Removal of the Prostate Start of enrollment: 2003 Feb 01
Completed
Phase 2
Exisulind Prior to Radical Prostatectomy Start of enrollment: 2002 Apr 01
Completed
Phase 2
Renal Hypothermia During Partial Nephrectomy Start of enrollment: 2012 Sep 01
Unknown status
Not Applicable
Trial of Intravesical Measles Virotherapy in Patients With Bladder Cancer Who Are Undergoing Radical Cystectomy Start of enrollment: 2018 Jul 20
Completed
Phase 1
Join now to see all

Publications & Presentations

PubMed

Renal Cell Carcinoma With Venous Tumor Thrombus Has a Predilection for the Lungs.
Reza Nabavizadeh, Rodrigo Rodrigues Pessoa, John C Cheville, Christine M Lohse, Brian A Costello
Urology. 2024-12-27
Evaluation of American Urological Association Renal Cell Carcinoma Risk Groups for Chromophobe Renal Cell Carcinoma.
Cameron J Britton, Vidit Sharma, Andrew Zganjar, Christine M Lohse, John C Cheville
Urology. 2024-12-01
Incidence and predictors of ipsilateral local recurrence following partial nephrectomy.
Cameron J Britton, Vidit Sharma, Christine M Lohse, Aaron M Potretzke, Stephen A Boorjian
Urologic Oncology. 2024-10-01

Journal Articles

Radical Versus Partial Nephrectomy for cT1 Renal Cell Carcinoma
Boris Gershman, Stephen A Boorjian, Bradley C Leibovich, European Urology
Use of Potentially Curative Therapies for Muscle-invasive Bladder Cancer in the United States: Results from the National Cancer Data Base Eur Urol 2013;63:823-9
Eisenberg MS, Leibovich BC, Kim SP. Re: Phillip J. Gray, Stacey A. Fedewa, William U. Shipley, et al, Eur Urol, 7/2/2013
Racial disparity in renal cell carcinoma patient survival according to demographic and clinical characteristics
Eisenberg MS, Leibovich BC, Kim SP, Cancer, 5/21/2013
Pro and extent
Leibovich BC, J Urol, 1/1/2013
Lymph node dissection at the time of radical nephrectomy for high-risk clear cell renal cell carcinoma: Indications and recommendations for surgical templates
Crispen PL, Breau RH, Allmer C, Lohse CM, Cheville JC, Leibovich BC, Blute ML, International Braz J Urol, 1/1/2011
Contemporary trends in nephrectomy for renal cell carcinoma in the United States: Results from a population based cohort
Kim SP, Shah ND, Weight CJ, Thompson RH, Moriarty JP, Shippee ND, Costello BA, Boorjian SA, Leibovich BC, International Braz J Urol, 1/1/2011
Reply from Authors re: Christian G Stief If a Partial Nephrectomy Could Be Done Safely for a Renal Tumor, Would Radical Nephrectomy Be Considered Malpractice?
Weight C, Leibovich B, Eur Urol, 1/1/2011
High sacrectomy for locally recurrent rectal cancer: Can long-term survival be achieved?
Dozois EJ, Privitera A, Holubar SD, Aldrete JF, Sim FH, Rose PS, Walsh MF, Bower TC, Leibovich BC, Nelson H, Larson DW, J Surg Oncol, 12/22/2010
Predicting disease progression after nephrectomy for localized renal cell carcinoma: the utility of prognostic models and molecular biomarkers
Crispen PL, Boorjian SA, Lohse CM, Leibovich BC, Kwon ED, J Urol, 5/1/2009
Carbonic anhydrase IX is not an independent predictor of outcome for patients with clear cell renal cell carcinoma
Leibovich BC, Sheinin Y, Lohse CM, Thompson RH, Cheville JC, Zavada J, Kwon ED, J Urol, 10/1/2008
Carbonic anhydrase IX expression in clear cell renal cell carcinomas negatively correlates with the proportion of the granular cell component - In reply
Leibovich BC, Sheinin Y, Lohse CM, Thompson RH, Cheville JC, Zavada J, Kwon ED, J Clin Oncol, 8/1/2008
Carbonic anhydrase IX as a predictive biomarker for clear cell renal cell carcinoma - Reply
Leibovich BC, Sheinin Y, Lohse CM, Thompson RH, Cheville JC, Zavada J, Kwon ED, J Clin Oncol, 6/20/2008
Predicting RCC outcomes: an update
Leibovich BC, Renal & Urology News, 8/1/2007
Significance of macroscopic tumor necrosis as a prognostic indicator for renal cell carcinoma - Editorial comment
Inman BA, Leibovich BC, J Urol, 10/1/2006
Aberrant expression of costimulatory B7-H1 in clear cell renal cell carcinoma
Thompson RH, Gillett MD, Cheville JC, Lohse CM, Dong H, Webster WS, Krejci KG, Lobo JR, Sengupta S, Chen L, Zincke H, Blute ML, Leibovich BC, Kwon ED, The American Journal of Urology Review, 1/1/2005
Immune cell marker expressed in kidney cancer and predicts aggressiveness
Kwon E, Thompson RH, Gillett M, Cheville J, Lohse C, Dong H, Webster WS, Krejci K, Lobo J, Sengupta S, Leiping C, Zincke H, Blute ML, Strome S, Leibovich BC, Cancer Biology and Therapy, 12/1/2004
Salvage radiotherapy may help prevent local recurrence of prostate cancer
Leibovich BC, Katz M, Wollman R, Radiological Socity of North America, Inc., 6/1/2004
A 40-year-old debate on lymphadenectomy continues How to decide when lymph node resection is indicated in localized RCC
Leibovich BC, Kidney Cancer Journal, 1/1/2004
Increased bcl-2 protein levels in prostatic adenocarcinomas are not associated with rearrangements in the 2 8 kb major breakpoint region or with P53 protein accumulation
Kallakury BVS, Figge J, Leibovich BC, Hwang J, Rifkin M, Kaufman R, Figge H, Nazeer T, Ross JS, Modern Pathology, 1/1/1996
Join now to see all

Press Mentions

Kidney CancerAugust 17th, 2024
The Power of AI: Advanced Algorithm IDs Heart Issues Using Apple Watch DataNovember 23rd, 2022
Study Shows Smartwatch EKG’s Ability to Accurately Detect Heart FailureNovember 15th, 2022
Join now to see all